© 2017 Freeman & Co. LLC

The information and services provided on this website are not provided to, and may not be used by, any person or entity in any jurisdiction where the provision or use thereof would be contrary to applicable laws, rules or regulations of any government authority or regulatory or self-regulatory organization or where Freeman & Co. or its affiliates is not authorized to provide such services or information.  Material on this website is not an offer to sell or a solicitation of an offer to buy any securities.  Transactions, products and services discussed on this website may not be appropriate for sale or use in all jurisdictions or for all investors.  The information on this website is not investment advice or other advice and should not be deemed a recommendation of any transaction or security.  Transactions described on this website are a selected sample and are not necessarily reflective of overall performance by Freeman & Co. or its affiliates.

  • Tumblr Social Icon
  • LinkedIn Social Icon
Please reload

Recent Posts

Healthcare ECM Recovery?

October 30, 2017

During the ’14-15 Healthcare boom, the sector reached 32% of the total U.S. ECM fee pool, the highest level any sector attained during the last decade. Starting in ’16, boom turned into bust, and the Healthcare sector’s contribution fell by more than half to 15%. As biotech stocks have started recovering this year, the Healthcare ECM market has followed suit. Firms which went public during market peak are now taking advantage of this bounce-back, raising funds with a flurry of follow-on issuances. Many of these follow-on issuers replaced original IPO bankers like Deutsche Bank, RBC, and Credit Suisse with relatively new players like Cantor Fitzgerald and Evercore. Moreover, well-established sector specialists like Cowen and Leerink have become bookrunner powerhouses and now hold higher market shares than they did during market peak.

 

 

Share on Facebook
Share on Twitter
Please reload

Follow Us